BioSpace News Archive

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today clarified certain prior disclosures regarding its relationship with Orphazyme A/S.

FUJIFILM Diosynth Biotechnologies U.S.A., Inc. (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and manufacture of their biologics, vaccines and gene therapies has announced that it has commenced the planned capacity expansion of its “Flexible Biomanufacturing Facility” at its College Station, Texas location

Dr. Dennis Gross, a New York City board-certified dermatologist with a background in skin cancer research, released a statement citing concerns after a new study published by the Food and Drug Administration (FDA) showed six common chemical sunscreen ingredients absorb into the bloodstream and greatly exceed levels considered safe

Global Down Syndrome Foundation announced eight new Global Self-Advocate Employment Initiative Grant winners at the national Down Syndrome Affiliates in Action Annual Leadership Conference.

VEO to Support The Masket Foundation in its Efforts to Raise Awareness of Aniridia and Other Rare Diseases

Prognos Health, an AI-driven platform company focused on predicting the trajectory of disease to drive informed decisions earlier in the patient journey, today announced the launch of the Rare Disease Institute (RDI), a collaborative initiative among critical healthcare stakeholders focused on improving testing, diagnosis and treatment of rare disease.

SpendEdge, a leading provider of procurement market intelligence solutions, has announced the completion of their latest success story on developing a successful commodity procurement strategy for a Fortune 500 global pharmaceutical company.

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced that Company management will present at the Raymond James 41st Annual Institutional Investors Conference, held on March 1-4, 2020 in Orlando, FL.

John Theurer Cancer Center at Hackensack University Medical Center is the only site in New Jersey and one of just 17 in the country participating in a multicenter international Phase II study of an innovative personalized cancer vaccine being evaluated in combination with pembrolizumab immunotherapy in patients with melanoma that has been surgically removed but has a high risk of coming back

Aptorum Group Limited, a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announced the closing of a registered direct offering of 1,351,350 Class A ordinary shares at a per share offering price of $7.40.